The application of psychedelics in psychiatry and psychotherapy is increasingly the subject of scientific evaluation and discussion in national and international professional and general society, and, internationally, has already been partly applied in the clinical setting. The manuscript provides a basic description of the state of the art regarding evidence and clinical issues; law, ethics and economics are addressed; therapeutic qualification of potential users and a potentially clinical embedding in psychiatry are discussed, taking into consideration current challenges. Thus, the discussion will cover the circumstances under which the application of psychedelics might have a potential to broaden the spectrum of treatments in certain psychiatric conditions, particularly in the context of chronicity and treatment resistance to current methods. However, basic and critical issues have to be clarified before eventual implementation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/a-2453-0910 | DOI Listing |
In August 2024, The U.S. Food and Drug Administration rejected Lykos Therapeutics, Inc.
View Article and Find Full Text PDFBrain Stimul
January 2025
Assistant Professor Co-Director, Center for Psychedelic Research and Therapy Department of Psychiatry & Behavioral Sciences Dell Medical School The University of Texas at Austin.
Clin Neuropharmacol
January 2025
Hospital del Mar Research Institute, Barcelona, Spain.
Objectives: This scoping review aimed to synthesize the existing data about psilocybin pharmacokinetics to learn what has been described regarding body disposition and safety when psilocybin was used in controlled research settings.
Methods: We performed a scoping literature review following the framework proposed by the JBI manual for evidence synthesis. Controlled clinical trials reporting pharmacokinetic data of psilocybin were considered appropriate for inclusion.
Int J Neuropsychopharmacol
January 2025
Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic Zurich and University of Zurich, Zurich, Switzerland.
Background: Recent interest in the clinical use of psychedelics has highlighted plant-derived medicines like ayahuasca showing rapid-acting and sustainable therapeutic effects in various psychiatric conditions. This traditional Amazonian plant decoction contains N,N-dimethyltryptamine (DMT) and β-carboline alkaloids such as harmine. However, its use is often accompanied by distressing effects like nausea, vomiting, and intense hallucinations, possibly due to complex pharmacokinetic/pharmacodynamic (PK-PD) interactions and lack of dose standardization.
View Article and Find Full Text PDFCurr Psychiatry Rep
January 2025
Department of Integrative Medicine and Nutritional Sciences, Thomas Jefferson University, 925 Chestnut Street, Suite 120, Philadelphia, PA, 19107, USA.
Purpose Of Review: Neurotheology is a nascent field of research and scholarship that seeks to understand the relationship between the brain and religious and spiritual phenomena. In the context of integrative psychiatry, neurotheology offers an intriguing intermediary between understanding how spirituality and religion affect brain function, and how this might be related to changes in mental health.
Recent Findings: A number of research studies over the years have observed that religious and spiritual beliefs, practices, and experiences can have a profound impact on a person's psyche.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!